Trial Profile
Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients With Non-infectious Uveitis
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Panuveitis; Uveitis
- Focus Therapeutic Use
- Acronyms SAVE-2
- 24 Oct 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2024.
- 24 Oct 2023 Planned primary completion date changed from 1 May 2022 to 1 Sep 2024.
- 24 Oct 2023 Planned initiation date changed from 1 Mar 2011 to 1 Sep 2022.